Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Nanostart-holding MagForce AG announces initiation of research coverage by Merchant Securities Limited

Abstract:
Nanostart (OTCQX: NASRY)-holding MagForce AG (FSE:MF6), a leading medical technology company focusing on nanomedicine in oncology, announced that Merchant Securities Limited has initiated research coverage on the company and published its first report. The report gives a buy recommendation and is available upon request from MagForce AG and Merchant Securities Limited or at tinyurl.com/czmb5uu.

Nanostart-holding MagForce AG announces initiation of research coverage by Merchant Securities Limited

Berlin /Frankfurt, Germany | Posted on November 23rd, 2011

"We are very pleased that Merchant Securites has taken up coverage of MagForce. The comprehensive report gives investors an independent view of the company, our novel technology for the treatment of brain tumors, and perspectives on our future growth and development" said Dr. Andreas Jordan, Founder and CSO at MagForce. "Merchant's head life science analyst, Dr. Navid Malik, has been following MagForce for some time and is a highly regarded equity research analyst with over fifteen years' experience in the pharmaceutical field, specifically in the area of oncology."

####

About Nanostart
Nanostart AG (OTCQX: NASRY), headquartered in the German financial capital of Frankfurt, is a leading nanotechnology investment company, with portfolio companies spanning the globe from Silicon Valley to Singapore. The company provides venture capital financing for nanotechnology companies in various growth phases with a focus on innovation-driven industries of the future such as cleantech, life sciences and IT/electronics. Through its subsidiary Nanostart Asia and the venture capital fund in Singapore, Nanostart is proud to be the investment partner of the Singaporean government. For further information please visit: www.nanostart.de.

About MagForce:

MagForce AG is a leading medical technology company focusing on nanomedicine in oncology. The company’s proprietary procedure, NanoTherm® therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of magnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator™ are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan and NanoActivator are trademarks of MagForce AG in selected countries. For further information please visit: www.magforce.com

About NanoTherm® therapy:

NanoTherm® therapy involves the direct injection of magnetic nanoparticles into the tumor and their subsequent heating by an alternating magnetic field. The water-soluble nanoparticles are approximately 15 nanometers in diameter and contain an iron oxide core with an aminosaline coating, which causes the particles to agglomerate following injection. The particles are then activated by a magnetic field that changes its polarity 100,000 times per second, and heat is produced within the tumor. Depending on the temperature reached and length of treatment, the tumor cells are either directly destroyed or sensitized for the accompanying chemotherapy or radiation.

Disclaimer:

This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within Canada, Australia or Japan.

For more information, please click here

Contacts:
Nanostart AG
Dr. Hans Joachim Duerr
Head of Corporate Communications
Goethestrasse 26-28
D-60313 Frankfurt, Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 150
e-mail:

Copyright © Nanostart AG

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Nanometrics to Announce Fourth Quarter and Full Year Financial Results on February 5, 2019 January 18th, 2019

ULVAC Inc., and Oxford Instruments Plasma Technology collaborate to bring Atomic Scale Processing solutions to the Japanese Power and RF markets January 18th, 2019

Kiel physicists discover new effect in the interaction of plasmas with solids January 18th, 2019

Brilliant glow of paint-on semiconductors comes from ornate quantum physics January 18th, 2019

Imaging

Chirality in 'real-time' January 14th, 2019

DNA design that anyone can do: Computer program can translate a free-form 2-D drawing into a DNA structure January 4th, 2019

Using sound to independently levitate a range of objects is achieved for the first time December 28th, 2018

Scientists use magnetic defects to achieve electromagnetic wave breakthrough December 20th, 2018

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

180 Degree Capital Corp.’s Portfolio Company, TheStreet, Inc., Agrees to Sell Its Institutional Business Units to Euromoney Institutional Investor PLC for $87.3 Million December 6th, 2018

180 Degree Capital Corp. Reports Net Asset Value Per Share of $2.81 as of September 30, 2018; a Decrease of 3.4% From June 30, 2018 October 29th, 2018

180 Degree Capital Corp. to Report Third Quarter 2018 Financial Results on Monday, October 29, 2018 and to Host a Conference Call on Tuesday, October 30, 2018 October 24th, 2018

180 Degree Capital Corp. Announces New Portfolio Holdings – Airgain, Inc., EMCORE Corporation, Lantronix, Inc. and PDL BioPharma, Inc. October 12th, 2018

Nanomedicine

Nanobiotix Plans to Conduct Registered Public Offering in the United States January 17th, 2019

Chirality in 'real-time' January 14th, 2019

Ultra-sensitive sensor with gold nanoparticle array January 9th, 2019

Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-ANG3 for Treatment of Dyslipidemias and Metabolic Diseases January 7th, 2019

Announcements

Nanometrics to Announce Fourth Quarter and Full Year Financial Results on February 5, 2019 January 18th, 2019

ULVAC Inc., and Oxford Instruments Plasma Technology collaborate to bring Atomic Scale Processing solutions to the Japanese Power and RF markets January 18th, 2019

Kiel physicists discover new effect in the interaction of plasmas with solids January 18th, 2019

Brilliant glow of paint-on semiconductors comes from ornate quantum physics January 18th, 2019

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project